Journal Article
. 2009 Dec; 51(2):228-35.
doi: 10.3109/10428190903440946.

A phase I study of dacetuzumab (SGN-40, a humanized anti-CD40 monoclonal antibody) in patients with chronic lymphocytic leukemia

Richard R Furman 1 Andres Forero-Torres  Andrei Shustov  Jonathan G Drachman  
  • PMID: 20038235
  •     36 citations


Despite advances in therapy, chronic lymphocytic leukemia remains an incurable disease and novel, effective therapies are needed. In this open-label, dose-escalation, phase I study, dacetuzumab (IgG1 humanized monoclonal antibody) was administered to 12 adults, all of whom had received several prior systemic therapies (median, 4; range, 2-11). Intrapatient dose escalation (maximum weekly doses of 3-8 mg/kg) was used to diminish first-dose-related inflammatory symptoms. No dose-limiting toxicities or dose-dependent trends in adverse events (AEs) were observed. The most common AEs (in >/=2 patients) were fatigue, headache, anorexia, conjunctivitis, hyperhidrosis, and night sweats, all of which were mild or moderate. No deaths, serious AEs, or discontinuations due to AEs occurred. Although no patient achieved an objective response, five patients demonstrated stable disease after 1 cycle of therapy, with no discernable correlation between dacetuzumab dose and outcome. This modest single-agent activity may warrant further testing of dacetuzumab in combination with other chronic lymphocytic leukemia therapies.

The clinical application of monoclonal antibodies in chronic lymphocytic leukemia.
Samantha M Jaglowski, Lapo Alinari, +2 authors, John C Byrd.
Blood, 2010 Jul 09; 116(19). PMID: 20610811    Free PMC article.
Autoimmune therapies targeting costimulation and emerging trends in multivalent therapeutics.
Chuda Chittasupho, Teruna J Siahaan, Charlotte M Vines, Cory Berkland.
Ther Deliv, 2011 Oct 11; 2(7). PMID: 21984960    Free PMC article.
Targeted treatment for chronic lymphocytic leukemia.
Aisha Masood, Taimur Sher, +3 authors, Asher Chanan-Khan.
Onco Targets Ther, 2011 Dec 14; 4. PMID: 22162923    Free PMC article.
Phase I study of the anti-CD40 humanized monoclonal antibody lucatumumab (HCD122) in relapsed chronic lymphocytic leukemia.
John C Byrd, Thomas J Kipps, +8 authors, Susan O'Brien.
Leuk Lymphoma, 2012 Apr 06; 53(11). PMID: 22475052    Free PMC article.
Targeting costimulatory molecules to improve antitumor immunity.
Daria Capece, Daniela Verzella, +2 authors, Edoardo Alesse.
J Biomed Biotechnol, 2012 Apr 14; 2012. PMID: 22500111    Free PMC article.
Immunotherapy of cancer in 2012.
John M Kirkwood, Lisa H Butterfield, +3 authors, Soldano Ferrone.
CA Cancer J Clin, 2012 May 12; 62(5). PMID: 22576456    Free PMC article.
Highly Cited. Review.
Therapeutic advancement of chronic lymphocytic leukemia.
Kang Lu, Xin Wang.
J Hematol Oncol, 2012 Sep 18; 5. PMID: 22980425    Free PMC article.
Clinical targeting of the TNF and TNFR superfamilies.
Michael Croft, Chris A Benedict, Carl F Ware.
Nat Rev Drug Discov, 2013 Jan 22; 12(2). PMID: 23334208    Free PMC article.
Highly Cited. Review.
The TNFRs OX40, 4-1BB, and CD40 as targets for cancer immunotherapy.
Amy E Moran, Magdalena Kovacsovics-Bankowski, Andrew D Weinberg.
Curr Opin Immunol, 2013 Feb 19; 25(2). PMID: 23414607    Free PMC article.
Agonistic CD40 antibodies and cancer therapy.
Robert H Vonderheide, Martin J Glennie.
Clin Cancer Res, 2013 Mar 06; 19(5). PMID: 23460534    Free PMC article.
Highly Cited.
Immune checkpoint blockade in cancer treatment: a double-edged sword cross-targeting the host as an "innocent bystander".
Lucia Gelao, Carmen Criscitiello, +2 authors, Giuseppe Curigliano.
Toxins (Basel), 2014 Mar 07; 6(3). PMID: 24594636    Free PMC article.
Trial Watch: Immunostimulatory monoclonal antibodies in cancer therapy.
Fernando Aranda, Erika Vacchelli, +5 authors, Lorenzo Galluzzi.
Oncoimmunology, 2014 Apr 05; 3(1). PMID: 24701370    Free PMC article.
Highly Cited.
Targeting CD8+ T-cell tolerance for cancer immunotherapy.
Stephanie R Jackson, Jinyun Yuan, Ryan M Teague.
Immunotherapy, 2014 Oct 08; 6(7). PMID: 25290416    Free PMC article.
New antibody approaches to lymphoma therapy.
Tejas Suresh, Lisa X Lee, Jitesh Joshi, Stefan K Barta.
J Hematol Oncol, 2014 Oct 31; 7. PMID: 25355407    Free PMC article.
CD40 expression and its prognostic significance in human gastric carcinoma.
Jing Guo, Jia-Jia Xiao, Xiaoli Zhang, Kai-Xi Fan.
Med Oncol, 2015 Feb 11; 32(3). PMID: 25665853
Human Anti-CD40 Antibody and Poly IC:LC Adjuvant Combination Induces Potent T Cell Responses in the Lung of Nonhuman Primates.
Elizabeth A Thompson, Frank Liang, +7 authors, Karin Loré.
J Immunol, 2015 Jul 01; 195(3). PMID: 26123354    Free PMC article.
The pharmacology of second-generation chimeric antigen receptors.
Sjoukje J C van der Stegen, Mohamad Hamieh, Michel Sadelain.
Nat Rev Drug Discov, 2015 Jul 02; 14(7). PMID: 26129802    Free PMC article.
Highly Cited. Review.
Expression, purification and biological characterization of the extracellular domain of CD40 from Pichia pastoris.
Yu Zhan, Yilei Wei, +8 authors, Xiaoren Zhang.
BMC Biotechnol, 2016 Jan 27; 16. PMID: 26809818    Free PMC article.
Enhancing the safety of antibody-based immunomodulatory cancer therapy without compromising therapeutic benefit: Can we have our cake and eat it too?
Joseph M Ryan, Jeffrey S Wasser, Adam J Adler, Anthony T Vella.
Expert Opin Biol Ther, 2016 Feb 09; 16(5). PMID: 26855028    Free PMC article.
Immunotherapy in Chronic Lymphocytic Leukaemia (CLL).
Ciara L Freeman, John G Gribben.
Curr Hematol Malig Rep, 2016 Feb 10; 11(1). PMID: 26857283    Free PMC article.
CD40 in coronary artery disease: a matter of macrophages?
Matthijs F Jansen, Maurits R Hollander, +2 authors, Esther Lutgens.
Basic Res Cardiol, 2016 May 06; 111(4). PMID: 27146510    Free PMC article.
Therapeutic Activity of Agonistic, Human Anti-CD40 Monoclonal Antibodies Requires Selective FcγR Engagement.
Rony Dahan, Bryan C Barnhart, +3 authors, Jeffrey V Ravetch.
Cancer Cell, 2016 Jun 07; 29(6). PMID: 27265505    Free PMC article.
Highly Cited.
Trial Watch: Immunostimulatory monoclonal antibodies for oncological indications.
Mariona Cabo, Rienk Offringa, +3 authors, Lorenzo Galluzzi.
Oncoimmunology, 2017 Dec 07; 6(12). PMID: 29209572    Free PMC article.
Monoclonal Antibody Therapies for Hematological Malignancies: Not Just Lineage-Specific Targets.
Carlos Cuesta-Mateos, Ana Alcaraz-Serna, Beatriz Somovilla-Crespo, Cecilia Muñoz-Calleja.
Front Immunol, 2018 Feb 02; 8. PMID: 29387053    Free PMC article.
Toward Small-Molecule Inhibition of Protein-Protein Interactions: General Aspects and Recent Progress in Targeting Costimulatory and Coinhibitory (Immune Checkpoint) Interactions.
Damir Bojadzic, Peter Buchwald.
Curr Top Med Chem, 2018 Jun 01; 18(8). PMID: 29848279    Free PMC article.
Complement System: a Neglected Pathway in Immunotherapy.
Anne Bordron, Cristina Bagacean, +4 authors, Yves Renaudineau.
Clin Rev Allergy Immunol, 2019 May 31; 58(2). PMID: 31144209
Antiangiogenic immunotherapy suppresses desmoplastic and chemoresistant intestinal tumors in mice.
Simone Ragusa, Borja Prat-Luri, +17 authors, Tatiana V Petrova.
J Clin Invest, 2020 Feb 06; 130(3). PMID: 32015230    Free PMC article.
Characteristics and clinical trial results of agonistic anti-CD40 antibodies in the treatment of malignancies.
Da-Ke Li, Wen Wang.
Oncol Lett, 2020 Sep 17; 20(5). PMID: 32934743    Free PMC article.
Extracellular Vesicles: New Players in Lymphomas.
Victor Navarro-Tableros, Yonathan Gomez, Giovanni Camussi, Maria Felice Brizzi.
Int J Mol Sci, 2018 Dec 26; 20(1). PMID: 30583481    Free PMC article.
Molecular basis and therapeutic implications of CD40/CD40L immune checkpoint.
TingTing Tang, Xiang Cheng, +3 authors, Hong Wang.
Pharmacol Ther, 2020 Oct 23; 219. PMID: 33091428    Free PMC article.
Engaging the Innate and Adaptive Antitumor Immune Response in Lymphoma.
Clifford M Csizmar, Stephen M Ansell.
Int J Mol Sci, 2021 Apr 04; 22(7). PMID: 33804869    Free PMC article.
Co-Stimulatory versus Cell Death Aspects of Agonistic CD40 Monoclonal Antibody Selicrelumab in Chronic Lymphocytic Leukemia.
Raquel Delgado, Karoline Kielbassa, +5 authors, Eric Eldering.
Cancers (Basel), 2021 Jul 03; 13(12). PMID: 34205588    Free PMC article.
Dendritic cell targeting with Fc-enhanced CD40 antibody agonists induces durable antitumor immunity in humanized mouse models of bladder cancer.
Christopher S Garris, Jeffrey L Wong, Jeffrey V Ravetch, David A Knorr.
Sci Transl Med, 2021 May 21; 13(594). PMID: 34011627    Free PMC article.
CD40 Agonist Monoclonal Antibody-Mediated Hepatitis in TNF-Receptor 1 Gene Knockout Mice.
Oksana Raabe, Thomas Birchler, Hubert Rehrauer, Elisabeth Eppler.
Biomedicines, 2021 Aug 28; 9(8). PMID: 34440067    Free PMC article.
Emerging immunotherapeutic strategies for the treatment of breast cancer.
Laura A Huppert, Veronica Mariotti, A Jo Chien, Hatem H Soliman.
Breast Cancer Res Treat, 2021 Oct 31; 191(2). PMID: 34716870
Emerging treatment strategies for metastatic triple-negative breast cancer.
Laura A Huppert, Ozge Gumusay, Hope S Rugo.
Ther Adv Med Oncol, 2022 Apr 16; 14. PMID: 35422881    Free PMC article.